<DOC>
	<DOC>NCT02896127</DOC>
	<brief_summary>To demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with ankylosing spondylitis at Week 16 and long term efficacy and safety up to Week 52.</brief_summary>
	<brief_title>Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male or nonpregnant, nonlactating female patients at least 18 years of age Diagnosis of moderate to severe AS with prior documented radiologic evidence (xray or radiologist's report) fulfilling the Modified New York criteria for AS: Active AS assessed by BASDAI ≥4 (010) at Baseline Spinal pain as measured by BASDAI question #2 ≥ 4 cm (010 cm) at Baseline Total back pain as measured by VAS ≥ 40 mm (0100 mm) at Baseline Patients should have had inadequate response or failure to respond to at least 2 NSAIDs at an approved dose for a minimum of 4 weeks in total and a minimum of 2 weeks for each NSAID prior to randomization, or less than 4 weeks if therapy had to be withdrawn due to intolerance, toxicity or contraindications Patients who are regularly taking NSAIDs (including COX1 or COX2 inhibitors) as part of their AS therapy are required to be on a stable dose for at least 2 weeks before randomisation Patients who have been on a TNFα inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to randomization or have been intolerant to at least one administration of an antiTNFα agent Chest Xray or MRI with evidence of ongoing infectious or malignant process Patients taking high potency opioid analgesics Previous exposure to secukinumab or any other biologic drug directly targeting IL17 or IL17 receptor Pregnant or nursing (lactating) women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Ankylosing Spondyloarthritis</keyword>
	<keyword>Axial spondyloarthritis</keyword>
</DOC>